Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KYMR Kymera Therapeutics, Inc.

Market Closed 10-09 16:00:00 EDT

112.40

+3.10

+2.84%

盘后112.40

+0.000.00%

19:30 EDT

High115.82	Low107.46	Vol1.31M
Open109.54	D1 Closing109.30	Amplitude7.65%
Mkt Cap9.35B	Tradable Cap7.46B	Total Shares83.15M
T/O147.59M	T/O Rate1.97%	Tradable Shares66.33M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":112.4,"timestamp":1791576000000,"preClose":109.3,"halted":0,"volume":1305180,"hourTrading":{"tag":"盘后","latestPrice":112.4,"preClose":112.4,"latestTime":"19:30 EDT","volume":7310,"amount":821644,"timestamp":1791588605731,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.028362305580969888,"floatShares":66325824,"shares":83150618,"eps":-3.212195,"marketStatus":"Market Closed","change":3.1,"latestTime":"10-09 16:00:00 EDT","open":109.54,"high":115.815,"low":107.4569,"amount":147585290.68440002,"amplitude":0.076469,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.212195,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791792000000},"marketStatusCode":7,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":109.3,"preHourTrading":{"tag":"盘前","latestPrice":109.46,"preClose":109.3,"latestTime":"09:29 EDT","volume":198,"amount":21690.92574,"timestamp":1791552599999,"change":0.16,"changeRate":0.001464,"amplitude":0.025526},"postHourTrading":{"tag":"盘后","latestPrice":112.4,"preClose":112.4,"latestTime":"19:30 EDT","volume":7310,"amount":821644,"timestamp":1791588605731,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.3673194743785413,"impliedVol":0.553,"impliedVolPercentile":0.1076},"requestUrl":"/m/hq/s/KYMR/tweets","defaultTab":"tweets","newsList":[{"id":"2674005210","title":"Kymera Therapeutics initiated with an Outperform at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2674005210","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674005210?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:15","pubTimestamp":1791490529,"startTime":"0","endTime":"0","summary":"Raymond James analyst Thomas Deal initiated coverage of Kymera Therapeutics (KYMR) with an Outperform rating and $140 price target Kymera’s pipelin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-initiated-with-an-outperform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-initiated-with-an-outperform-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673389081","title":"Kymera Therapeutics is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2673389081","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673389081?lang=en_us&edition=fundamental","pubTime":"2026-10-06 03:32","pubTimestamp":1791228720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYMR/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673457709","title":"Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $150 from $135","url":"https://stock-news.laohu8.com/highlight/detail?id=2673457709","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673457709?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:13","pubTimestamp":1791195232,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nFWN45R0NF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672675167","title":"Kymera Therapeutics CEO Nello Mainolfi Disposes of USD 3.39 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2672675167","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672675167?lang=en_us&edition=fundamental","pubTime":"2026-10-02 05:20","pubTimestamp":1790889644,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics CEO Nello Mainolfi disposes of USD 3.39 million in common sharesKymera Therapeutics CEO Nello Mainolfi exercised options for 30,000 shares at $2.08 on Oct. 1, 2026.He sold 30,000 s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL50FhMZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Kymera Therapeutics CEO Nello Mainolfi Disposes of USD 3.39 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672662237","title":"JPMorgan SMid biotech analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2672662237","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672662237?lang=en_us&edition=fundamental","pubTime":"2026-10-02 00:50","pubTimestamp":1790873411,"startTime":"0","endTime":"0","summary":"SMid Biotechnology Analysts Cheng and Medeiros discuss their view on Kymera Therapeutics’s (KYMR) STATS readout in atopic dermatitis on an Analyst/...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/jpmorgan-smid-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/jpmorgan-smid-biotech-analysts-hold-an-analyst-industry-conference-call-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0238689110.USD","IE00BFXG1179.USD","XBIX","LU0265550946.USD","LU2357627491.SGD","JPO","IE00BJTD4V19.USD","IE00BZ1G4Q59.USD","LU2236285917.USD","JPM","LU1244550577.SGD","LU2054465674.USD","LU2505996509.AUD","IXG","BK4585","LU2213496289.HKD","LU0971096721.USD","FNCL","LU2552382132.HKD","LU0256863902.USD","KYMR","LU0943347566.SGD","LU0820562030.AUD","TRUF","KBWB","LU0320765489.SGD","IYF","SG9999002224.SGD","LU2168563687.JPY","TFNS","VFH","LU1064131342.USD","JPMO","NVIB","LU0211326755.USD","UYG","XLF","IE00BN8TJ469.HKD","LU0106831901.USD","IE00B3S45H60.SGD","LU0345769631.USD","LU1917777945.USD","IE000BZT7R73.USD","LU2168564222.USD","LU0234572021.USD","FTXO","BK4139","BK4207","IYG","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234677","title":"Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234677","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670234677?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:36","pubTimestamp":1790595394,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Brian Cheng placed Kymera Therapeutics (KYMR) on “Positive Catalyst Watch” while keeping an Overweight rating on the shares with a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-placed-on-positive-catalyst-watch-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-placed-on-positive-catalyst-watch-at-jpmorgan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4504","KBWB","LU1366333091.USD","IE0034235295.USD","IE0034235188.USD","IE00BDRTCR15.USD","JPMO","LU1032466523.USD","LU0787776722.HKD","LU1551013342.USD","LU0868494708.USD","IYF","LU2756315664.SGD","IE00BHPRN162.USD","LU0859254822.USD","UYG","LU0006306889.USD","VFH","IE0034235303.USD","LU1496350502.SGD","LU2237443382.USD","IXG","LU1162221912.USD","IE00BJTD4N35.SGD","LU2381873111.SGD","TRUF","LU2023250504.SGD","XLF","JPO","LU0234572021.USD","LU2430703251.USD","FNCL","LU0238689110.USD","LU0310799852.SGD","LU1244550221.USD","TFNS","FTXO","PGF","KYMR","LU0048584097.USD","BK4566","LU1720051017.SGD","LU2417539215.USD","LU0942090050.USD","LU0211327993.USD","IE00BN8TJ469.HKD","LU0256863902.USD","BK4533","IYG","LU0964807845.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669902465","title":"Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2669902465","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669902465?lang=en_us&edition=fundamental","pubTime":"2026-09-24 16:50","pubTimestamp":1790239811,"startTime":"0","endTime":"0","summary":"Goldman Sachs analyst Andrea Newkirk resumed coverage of Kymera Therapeutics (KYMR) with an Early-Stage Biotech rating. Goldman resumed coverage of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-resumed-with-early-stage-biotech-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-resumed-with-early-stage-biotech-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","LU0048573561.USD","LU0868494617.USD","LU1868836591.USD","LU1144417596.USD","LU0210536198.USD","LU2750360641.GBP","LU0251142724.SGD","BK4581","IE00BSNM7G36.USD","LU1791807156.HKD","IE0004086264.USD","LU0868494708.USD","BK4516","IE00B19Z3B42.SGD","LU2471134952.CNY","LU0096364046.USD","LU1894683348.USD","IE0034235188.USD","IE0002270589.USD","BK4585","LU0061475181.USD","LU2750360997.AUD","BK4139","LU1894683264.USD","IE00B19Z3581.USD","LU2237443382.USD","LU0345770993.USD","LU2237443895.HKD","LU2237443549.SGD","LU0742534661.SGD","BK4504","LU1868837300.USD","BK4127","LU1868836757.USD","LU1868836914.USD","GSX","LU2471134523.USD","LU2237443978.SGD","LU0345770308.USD","LU1668664300.SGD","XBI","BK4588","KYMR","LU2265009873.SGD","IE00BFXG1179.USD","LU2237443622.USD","LU0251131958.USD","LU1804176565.USD","LU2896262040.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669648508","title":"Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669648508","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669648508?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:30","pubTimestamp":1790166641,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nek...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kymera-therapeutics-kymr-vertex-pharmaceuticals-vrtx-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kymera-therapeutics-kymr-vertex-pharmaceuticals-vrtx-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","LU0823416689.USD","IBB","IE00B894F039.SGD","IE00BZ9MQY76.HKD","LU0109394709.USD","NKTR","LU0432979614.USD","LU1674673428.USD","LU0256863811.USD","LU1559883803.SGD","LU2362541513.USD","LU2237438978.USD","TBXU","LU2417539215.USD","IE00BJJMRZ35.SGD","IE00B19Z3B42.SGD","BK4023","LU0417517546.SGD","IE0002141913.USD","PBE","BK4007","LU1069344957.HKD","IE0002270589.USD","BK4585","LU0061475181.USD","BK4139","IE00B19Z3581.USD","LU0757428866.USD","HCSG","BIB","VRTX","LU2324357040.USD","SG9999001176.USD","XLV","IE00BFTCPJ56.SGD","LU0234570918.USD","IDNA","VERX","BBH","KYMR","LU1035775433.USD","XBI","GNMX","LU0289739699.SGD","SG9999001176.SGD","LU2089984988.USD","IBBQ","LABU","LU2362541273.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143006","title":"Kymera Therapeutics, Inc. : Stifel Raises Target Price to $152 from $132","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143006?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:22","pubTimestamp":1790072528,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nFWN45E055:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669111886","title":"US Research Roundup-Boeing, Twilio, WP Carey","url":"https://stock-news.laohu8.com/highlight/detail?id=2669111886","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669111886?lang=en_us&edition=fundamental","pubTime":"2026-09-22 15:01","pubTimestamp":1790060472,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Boeing, Twilio, WP CareySept 22 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Boeing, Twilio and W.P. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nL4N45E0CX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DHI","BMNR","ABVX","DAR","KYMR","USAI","GEHC","FICO","TPZ","IONS","CXT","ENFR","ET","CCL","LNG","AM","CTAS","BA","CHPT","CWEN","BOEG","EPD","FXN","CNTB","CALM","YBMN","KBR","FDIQ","CHRD","CABO","APH","PKB","IRMD","GKOS","BFLY","FWDI","HTFL","ALK","CMCSA","BEAT","JMSB","RNWZ","EFX","FDS","AMRZ","T","MLPI","FITB","KMI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667135622","title":"Kymera Therapeutics management to meet with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2667135622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667135622?lang=en_us&edition=fundamental","pubTime":"2026-09-16 04:50","pubTimestamp":1789505416,"startTime":"0","endTime":"0","summary":"Meeting to be held on September 21 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-management-to-meet-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667988946","title":"Kymera Therapeutics Price Target Raised to $144.00/Share from $123.00 by B of a Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988946","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667988946?lang=en_us&edition=fundamental","pubTime":"2026-09-15 01:57","pubTimestamp":1789408620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYMR/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665225","title":"BofA Securities Adjusts Kymera Therapeutics Price Target to $144 From $123","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665225","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665225?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:21","pubTimestamp":1789388461,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (KYMR) has an average rating of buy and mean price target of $137.73, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666591075","title":"Wolfe upgrades Kymera Therapeutics to Outperform on potential upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2666591075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666591075?lang=en_us&edition=fundamental","pubTime":"2026-09-10 22:25","pubTimestamp":1789050331,"startTime":"0","endTime":"0","summary":"As previously reported, Wolfe Research upgraded Kymera Therapeutics (KYMR) to Outperform from Peer Perform with an $180 price target After engineer...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wolfe-upgrades-kymera-therapeutics-to-outperform-on-potential-upside-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wolfe-upgrades-kymera-therapeutics-to-outperform-on-potential-upside-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666599947","title":"Kymera Therapeutics Raised to Outperform from Peer Perform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2666599947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666599947?lang=en_us&edition=fundamental","pubTime":"2026-09-10 21:45","pubTimestamp":1789047900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KYMR/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733129","title":"J.P. Morgan Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733129","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664733129?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:06","pubTimestamp":1788523564,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Brian Cheng maintained a Buy rating on Kymera Therapeutics yesterday and set a price target of $140.00. The company’s shares cl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-buy-rating-for-kymera-therapeutics-kymr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-its-buy-rating-for-kymera-therapeutics-kymr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KYMR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664849810","title":"Kymera Therapeutics to Participate in Upcoming September Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2664849810","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664849810?lang=en_us&edition=fundamental","pubTime":"2026-09-03 04:01","pubTimestamp":1788379260,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicin","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355474/0/en/kymera-therapeutics-to-participate-in-upcoming-september-investor-conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664166810","title":"Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664166810","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664166810?lang=en_us&edition=fundamental","pubTime":"2026-09-02 22:59","pubTimestamp":1788361153,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics' (KYMR) KT-621 could validate its \"oral Dupixent\" potential, but with a roughly $13 billion valuation, upside looks limited ahead of the data, RBC Capital Markets said in a note We","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0541502299.USD","LU0541501648.USD","KYMR","SG9999004220.SGD","KT","BK4115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664894271","title":"U.S. Research Roundup-Adobe, Dell Technologies, Zscaler","url":"https://stock-news.laohu8.com/highlight/detail?id=2664894271","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664894271?lang=en_us&edition=fundamental","pubTime":"2026-09-02 15:46","pubTimestamp":1788335191,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Adobe, Dell Technologies, ZscalerSept 2 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Dell ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4N44U0MN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDB","BRZE","MTRN","HAWK","DLLL","WCLD","SAIC","REA","PSR","ASTS","ENOV","ADBE","GWRE","KYMR","PANW","DOCU","ESI","SUNB","EYPT","NB","WELL","AMRZ","RKLX","RKLB","WCBR","PL","EIX","VNQ","DELL","CIBR","MMED","SPAM","ASO","GTLB","ALMS","ZS","ORCL","ASTX","KNF","TDIV","JRE","USAR","MLM","CRK","ERET","ALM","OGE","IPX.AU","SRE","FSPC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664609891","title":"Kymera Therapeutics, Inc. : JP Morgan Raises Target Price to $140 from $121","url":"https://stock-news.laohu8.com/highlight/detail?id=2664609891","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664609891?lang=en_us&edition=fundamental","pubTime":"2026-09-02 15:04","pubTimestamp":1788332697,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nFWN44U0PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":0.0467},{"period":"1month","weight":-0.0262},{"period":"3month","weight":-0.0582},{"period":"6month","weight":0.3216},{"period":"1year","weight":0.9712},{"period":"ytd","weight":0.4445}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.060685},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.014692},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.075866},{"month":4,"riseRate":0.5,"avgChangeRate":0.006528},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.121889},{"month":6,"riseRate":0.666667,"avgChangeRate":0.163264},{"month":7,"riseRate":0.666667,"avgChangeRate":0.127227},{"month":8,"riseRate":0.666667,"avgChangeRate":0.054225},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.035696},{"month":10,"riseRate":0.714286,"avgChangeRate":0.060434},{"month":11,"riseRate":0.666667,"avgChangeRate":0.180891},{"month":12,"riseRate":0.666667,"avgChangeRate":0.094258}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}